Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Salamanca – page 19

441 clinical trials in Salamanca, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Salamanca at a glance
441
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

441 trials in Salamanca

Open in trial search

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Dementia Alzheimer's type

Not recruiting

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gsk4527226
  • Sponsor:Glaxosmithkline Research & Development Limited

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Haematological malignancy+1

Not recruiting

Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Chronic kidney disease

Not recruiting

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Arteriosclerosis

Not recruiting

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Waldenstrom's macroglobulinaemia+1

Not recruiting

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Chronic spontaneous urticaria

Not recruiting

Study on the Effects of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Evommune Inc.

Plasma cell myeloma

Not recruiting

Study on the Safety and Effectiveness of Anitocabtagene Autoleucel and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Factor VIII deficiency

Not recruiting

Study on Long-Term Effects of Efanesoctocog Alfa in Preventing Joint Bleeds in Patients with Hemophilia A

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Salamanca

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on various types of lymphomas and leukemias, including innovative combination therapies for mantle cell lymphoma and chronic myeloid leukemia. Multiple trials are evaluating novel treatment approaches for both newly diagnosed and refractory cases.

  • Blood Cancers
  • Solid Tumors
  • Targeted Therapies

Research includes promising treatments for pancreatic adenocarcinoma and advanced breast cancer.

02 Respiratory Medicine

Investigations into preventing and treating respiratory syncytial virus infections, with particular focus on vaccine development for older adults. Studies aim to understand immune responses and evaluate preventive strategies.

  • Viral Infections
  • Vaccine Development
  • Elderly Care

Clinical trials emphasize protection for vulnerable populations against respiratory infections.

03 Immunology Studies

Research addressing chronic spontaneous urticaria and autoimmune conditions, including innovative treatments for systemic sclerosis. Studies evaluate new therapeutic approaches for inflammatory conditions.

  • Autoimmune Disorders
  • Allergic Conditions
  • Novel Therapeutics

Trials focus on improving patient outcomes through targeted immunological interventions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.